All Filters
Therapeutic Area
Therapeutic Area
Format
What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Format
top

Ilaris resources for HCPs

Indications1

Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

  • Cryopyrin-associated periodic syndromes (CAPS), including:

    • Muckle-Wells syndrome (MWS)

    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)

    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash

  • Tumour necrosis factor receptor associated periodic syndrome (TRAPS)

  • Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)

  • Familial Mediterranean Fever (FMF)

    • ILARIS should be given in combination with colchicine, if appropriate

Still’s disease
ILARIS is indicated in patients who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids, for the treatment of active Still’s disease, including:

  • Adult-onset Still’s disease (AOSD) 

  • Systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older 

  • ILARIS can be given as monotherapy or in combination with methotrexate 

Gouty arthritis
ILARIS is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

Below are resources for HCPs to support the use of ILARIS in day-to-day practice.

If the HCP determines that it is appropriate (and with medical follow-up as necessary), patients or their caregivers may inject ILARIS after proper training in the correct injection technique.

ILARIS Homecare is a patient support programme created and funded by Novartis Pharmaceuticals UK Ltd.

AOSD, adult-onset Still’s disease; CAPS, cryopyrin-associated periodic syndromes; CINCA, chronic infantile neurological, cutaneous, articular syndrome; FCAS, familial cold autoinflammatory syndrome; FCU, familial cold urticaria; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease; NSAID, non-steroidal anti-inflammatory drug; PFS, periodic fever syndrome; SJIA, systemic juvenile idiopathic arthritis; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

References

  1. ILARIS® (canakinumab) Summary of Product Characteristics.

  2. Pharmaxo Healthcare. How We Work. Available at: https://pharmaxohealthcare.com/patients/new-patient/how-we-work/ [Accessed May 2025].

  3. Pharmaxo Healthcare. NHS Services. Available at: https://pharmaxohealthcare.com/services/ [Accessed May 2025].

  4. Pharmaxo Healthcare. Patient FAQs. Available at: https://pharmaxohealthcare.com/support/faqs/ [Accessed May 2025].

  5. Sciensus. Long-term conditions. Available at: https://www.sciensus.com/long-term-conditions/ [Accessed May 2025].

  6. Hackett, M. Homecare Medicines: Towards a Vision For the Future. NHS, Department of Health. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploa... [Accessed May 2025].

ilaris-blue-article-card-background
Safety profile in PFS
Safety profile in PFS
See more details

UK | May 2025 | FA-11327910-1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.